publication banner
publications-mobile banner

Publications

Discover peer-reviewed publications by therapeutic area.
The information on this page pertains to select publication resources. It is not intended to serve as a comprehensive list of all publications resources.
If you would like to discover more educational content, please use the “Search” feature.

Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
The provision of this content is not intended to recommend or suggest use of its products in any manner inconsistent with local regulatory approval. For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Publications

Transthyretin Amyloidosis (ATTR)

Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

New England Journal of Medicine

Author(s)

Marianna Fontana, John L. Berk, Julian D. Gillmore, et al

Primary Hyperoxaluria Type 1 (PH1)

Reducing diagnostic delays in acute hepatic porphyria using health records data and machine learning

Journal of the American Medical Informatics Association

Author(s)

Balu Bhasuran, Katharina Schmolly, Yuvraaj Kapoor, et al

Transthyretin Amyloidosis (ATTR)

Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy

European Journal of Neurology

Author(s)

Celine Labeyrie, Madeline Merkel, Sakshi Sethi, et al

Transthyretin Amyloidosis (ATTR)

Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review

Journal of Comparative Effectiveness Research

Author(s)

Jose Nativi-Nicolau, Ali Yilmaz, Noel Dasgupta, et al

Acute Hepatic Porphyria (AHP)

A randomized, placebo-controlled study of givosiran in patients with acute hepatic porphyrias (ENVISION): Final (36-month) analysis of the Taiwan Cohort

Journal of the Formosan Medical Association

Author(s)

Ming-Jen Lee, Hung-Chou Kuo, Lin-Na Chou, et al

Primary Hyperoxaluria Type 1 (PH1)

Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1: Results from a Phase III Clinical Trial

Kidney International Reports

Author(s)

Jeffrey M. Saland, John C. Lieske, Jaap W. Groothoff, et al

Transthyretin Amyloidosis (ATTR)

Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study

Neurology and Therapy

Author(s)

Marco Luigetti, Dianna Quan, John L. Berk, et al

Acute Hepatic Porphyria (AHP)

Elevated homocysteine is negatively correlated with plasma cystathionine β ‐synthase activity in givosiran‐treated patients

Journal of Inherited Metabolic Disease Reports

Author(s)

Mark A. Keibler, Gautham V. Sridharan, Marianne T. Sweetser, et al

Transthyretin Amyloidosis (ATTR)

Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study

Journal of the Formosan Medical Association

Author(s)

Lin KP, Yang CC, Lee YC, et al

Cardiovascular (CV)

RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial

The Journal of the American Medical Association

Author(s)

George L Bakris, Manish Saxena, Anil Gupta, et al